Device Trial Radar · NCT03038438
ABRE Clinical Study of the Abre Venous Self-expanding Stent System
Last checked: Nov 20, 2026Latest source record: Nov 8, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
260
Actual
Start
Dec 13, 2017
Primary completion
Jan 14, 2020
Study completion Jan 28, 2022
Sponsor
- Lead sponsor
- Medtronic EndovascularPublic (MDT)
- Sponsor type
- Industry
- First posted
- Jan 31, 2017
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Evaluate the safety and effectiveness of the Abre venous self-expanding stent system for treatment of symptomatic iliofemoral venous outflow obstruction in patients with venous occlusive disease.
Conditions
- Iliofemoral Venous Obstruction
Interventions
Abre venous self-expanding stent systemDevice
venous stent
Primary outcomes
What the sponsor says the trial is designed to measure.
- Primary PatencyTime frame: 12 Months
- Composite Major Adverse EventsTime frame: 30 Days
Locations
24 sites in 6 countries. Site status is shown where the registry gives one.
St. Joseph Hospital
Orange, California
The Vascular Experts
Darien, Connecticut
Piedmont Atlanta Hospital
Atlanta, Georgia
21 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.